Has the Dutch Biotech Industry valuation changed over the past few years?

There are only 3 companies in the Dutch Biotechs industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.

Which industries have driven the changes within the Dutch Healthcare industry?

There are no additional sub-industries under this industry.

Dutch (AEX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 22 Jun 2026	€2.5b	€1.4b	€489.8m	38.7x	5x	1.8x
Wed, 20 May 2026	€2.3b	€1.4b	€489.7m	37.8x	4.7x	1.7x
Fri, 17 Apr 2026	€2.7b	€1.4b	€309.4m	220x	8.7x	1.9x
Sun, 15 Mar 2026	€2.7b	€1.4b	€309.5m	180.3x	8.9x	1.9x
Tue, 10 Feb 2026	€2.8b	€591.5m	-€456,033,852.60	2937.7x	-6.2x	4.8x
Thu, 08 Jan 2026	€2.9b	€596.9m	-€456,028,160.80	3085.7x	-6.4x	4.9x
Sat, 06 Dec 2025	€2.8b	€598.3m	-€456,026,671.00	2942.3x	-6.1x	4.7x
Mon, 03 Nov 2025	€2.6b	€570.4m	-€308,044,500.00	n/a	-8.6x	4.6x
Wed, 01 Oct 2025	€2.8b	€565.1m	-€307,915,760.00	n/a	-9.1x	5x
Fri, 29 Aug 2025	€2.7b	€566.5m	-€316,035,380.00	n/a	-8.7x	4.8x
Sun, 27 Jul 2025	€2.4b	€548.7m	-€321,064,956.80	n/a	-7.5x	4.4x
Tue, 24 Jun 2025	€2.2b	€565.2m	-€212,095,945.60	n/a	-10.3x	3.9x
Thu, 22 May 2025	€2.4b	€571.4m	-€212,366,896.00	n/a	-11.3x	4.2x
Sat, 19 Apr 2025	€1.9b	€536.5m	-€11,673,661.60	n/a	-164.4x	3.6x
Mon, 17 Mar 2025	€2.1b	€548.7m	-€11,414,710.30	n/a	-184.9x	3.8x
Wed, 12 Feb 2025	€2.0b	€536.3m	-€77,838,711.80	n/a	-26.3x	3.8x
Fri, 10 Jan 2025	€2.4b	€537.6m	-€77,918,915.30	n/a	-30.6x	4.4x
Sun, 08 Dec 2024	€2.2b	€530.6m	-€77,485,816.40	n/a	-28.3x	4.1x
Tue, 05 Nov 2024	€2.1b	€522.8m	-€76,997,466.20	n/a	-27.9x	4.1x
Thu, 03 Oct 2024	€2.2b	€512.1m	€19.5m	53.7x	112.2x	4.3x
Sat, 31 Aug 2024	€2.2b	€512.5m	€19.4m	55.2x	114x	4.3x
Mon, 29 Jul 2024	€2.2b	€481.5m	€20.8m	53.9x	104.8x	4.5x
Wed, 26 Jun 2024	€2.1b	€484.7m	€20.6m	51.6x	101.9x	4.3x
Fri, 24 May 2024	€2.3b	€482.6m	€20.7m	55.2x	108.6x	4.7x
Sun, 21 Apr 2024	€2.4b	€470.0m	-€40,178,407.60	n/a	-59.6x	5.1x
Tue, 19 Mar 2024	€2.7b	€465.4m	-€39,587,491.90	n/a	-69.4x	5.9x
Thu, 15 Feb 2024	€3.3b	€747.8m	-€199,915,465.50	n/a	-16.7x	4.5x
Sat, 13 Jan 2024	€3.3b	€743.7m	-€199,494,215.00	n/a	-16.8x	4.5x
Mon, 11 Dec 2023	€3.3b	€747.2m	-€199,847,095.00	n/a	-16.6x	4.4x
Wed, 08 Nov 2023	€3.3b	€748.6m	-€199,994,864.00	n/a	-16.5x	4.4x
Fri, 06 Oct 2023	€3.1b	€756.2m	-€199,236,025.00	n/a	-15.8x	4.2x
Sun, 03 Sep 2023	€3.4b	€751.6m	-€200,741,829.00	n/a	-17.1x	4.6x
Tue, 01 Aug 2023	€3.6b	€730.7m	-€211,440,263.00	n/a	-17.1x	5x
Thu, 29 Jun 2023	€3.4b	€732.6m	-€211,459,016.00	n/a	-16.2x	4.7x


NL Market	1.03%
Healthcare	1.56%
Biotech	-0.77%
Biotech	-0.77%

	Company	Last Price	7D	1Y	Valuation
	PHARM Pharming Group	€1.14	2.3% +€17.7m	25.9%	PE74.3x

Announcement • Jun 04

Pharming Group N.V. Announces U.S. FDA Acceptance of sNDA Resubmission for Joenja (Leniolisib) to Treat Children Aged 4 to 11 Years with APDS

Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3K) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. Following the Complete Response Letter (CRL) received on January 30, 2026, and a subsequent Type A meeting with the FDA on March 26, 2026, the resubmission seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing 27 kg or more, who represent a meaningful proportion of the identified pediatric patient population. The resubmission includes additional data requested by the FDA on analytical methods used for production batch testing. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026. A separate sNDA seeking approval for lower doses for patients weighing less than 27 kg is planned for this summer. The resubmission is supported by positive data from the open-label, multinational, single-arm Phase III study in children aged 4 to 11 years, which showed improvements over 12 weeks in two clinically relevant hallmarks of APDS, reduced lymphadenopathy and increased na ve B cells, together indicating a correction of the underlying immune defect. The improvements in lymphoproliferation and immunophenotype correction were seen across all dose levels investigated and were consistent with the improvements previously reported in adolescent and adult patients. All treatment emergent adverse events were reported to be mild to moderate in nature. There were no drug related serious adverse events, and all patients completed the 12-week treatment period. Joenja received approval from the FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023. APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3K (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation. APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy. Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay. As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma. A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide. Leniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3K) inhibitor approved as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3K) syndrome (APDS) in the U.S., U.K., Australia and Israel in adult and pediatric patients 12 years of age and older and in Japan for patients 4 years of age and older. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and open label extension data has supported the safety and tolerability of long-term leniolisib administration. Leniolisib is currently under regulatory review for the treatment of APDS in Canada and several other countries. Leniolisib is also being evaluated in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS.

Dutch (AEX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Lakefront Biotherapeutics NV (ENXTAM:LKFT) commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on April 28, 2026.

Vivoryon Therapeutics N.V. to Report Q1, 2026 Results on Jun 11, 2026

Pharming Group N.V. Announces U.S. FDA Acceptance of sNDA Resubmission for Joenja (Leniolisib) to Treat Children Aged 4 to 11 Years with APDS